One in two Australians will be diagnosed with cancer during their lifetime. Most anti-cancer drugs are cytotoxic with significant side effects. Highly selective drugs with minimal toxicity are critically needed.
DDB's studies investigate the tumour microenvironment as a novel therapeutic target. We study the peripheral nervous system and its capacity to regulate key tumour processes, including metastasis, inflammation, angiogenesis and hypoxia.
We are evaluating drugs that interact with the peripheral nervous system as novel strategies to limit cancer progression, and working with medicinal chemists to design and evaluate new anti-cancer compounds.
GPCR signalosomes and compartmentalization
protein complexes, signal compartmentalisation, spatiotemporal signalling, cAMP, ERK, receptor trafficking, cancer
Neural Regulation of Cancer
cancer, stress, symptoms, treatment, metastasis, molecular and cellular mechanisms, imaging, behaviour, mouse models
Male reproductive pharmacology
male contraception, benign prostatic hyperplasia, prostate cancer, vas deferens, adrenoceptors, purinoceptors